Eleftheria Maratos-Flier

Last updated

Eleftheria Maratos-Flier is an American endocrinologist, [1] and emerita Professor of Medicine at Harvard Medical School, [2] best known for her expertise in the pathophysiology and prevention of obesity-related metabolic disorders, [3] [4] and for her discoveries on the neuroendocrine control of feeding behaviour. [5] [6] She is a contributing author to known textbooks and reviews in internal medicine, [7] endocrinology, [8] and physiology. [9] Her marriage with professor Jeffrey Flier, was noted by Forbes [10] as a lasting and productive bond between eminent medical scholars. [11] They have two adult daughters who are also physicians. She is also known as Terry Maratos-Flier. [12]

Contents

Education

In 1972, she graduated with a BA in Chemistry from New York University, New York, NY. [13] In 1976, she graduated as an MD from the Mount Sinai School of Medicine, New York, NY, [14] followed by internship and residency training in internal medicine at George Washington University Hospital, Washington, DC. [15] In Massachusetts (1978-1981), she pursued further residency training in internal medicine at Beth Israel Hospital, postdoctoral research fellowship at Harvard School of Public Health, and Clinical Fellowship at the Joslin Diabetes Center and Brigham and Women’s Hospital. [2] [15]

Career

Since 1982 she has taught at Harvard Medical School, becoming a full Professor of Medicine from 2010 to 2018, when she became professor emerita. [16] She has been an associate member of the Broad Institute, [17] and a Principal Investigator of many NIH-funded research grants. [18] She has also been an attending endocrinologist at Beth Israel Deaconess Medical Center, where she still provides care for patients with metabolic disease. [19] From 2018, she has been Director, Translational Medicine, at Novartis Institutes of Biomedical Research, Cambridge, MA., [20] recently moving to Alnylam to serve as a director of clinical research. She has authored more than 100 peer-reviewed papers, [21] most of them studying aspects of obesity and type II diabetes in experimental mouse models, and also in clinical disease. She also authored the obesity chapters of the 20th edition of Harrison's Principles of Internal Medicine (jointly with Jeffrey Flier), [7] and the 14th edition of Williams Textbook of Endocrinology. [8] In 2016, she contributed an article to the Annual Review of Physiology on the physiology of Fibroblast Growth Factor 21. [9]

Awards

Selected works

Maratos-Flier's research papers have been cited over 15,600 times. [21] Her most cited papers are:

Related Research Articles

Insulin resistance (IR) is a pathological condition in which cells either fail to respond normally to the hormone insulin or downregulate insulin receptors in response to hyperinsulinemia.

<span class="mw-page-title-main">Proopiomelanocortin</span> Mammalian protein found in Homo sapiens

Pro-opiomelanocortin (POMC) is a precursor polypeptide with 241 amino acid residues. POMC is synthesized in corticotrophs of the anterior pituitary from the 267-amino-acid-long polypeptide precursor pre-pro-opiomelanocortin (pre-POMC), by the removal of a 26-amino-acid-long signal peptide sequence during translation. POMC is part of the central melanocortin system.

<span class="mw-page-title-main">Leptin</span> Hormone that inhibits hunger

Leptin is a protein hormone predominantly made by adipocytes and its primary role is likely to regulate long-term energy balance.

<span class="mw-page-title-main">Adipose tissue</span> Loose connective tissue composed mostly by adipocytes

Adipose tissue (also known as body fat, or simply fat) is a loose connective tissue composed mostly of adipocytes. In addition to adipocytes, adipose tissue contains the stromal vascular fraction(SVF) of cells including preadipocytes, fibroblasts, vascular endothelial cells and a variety of immune cells such as adipose tissue macrophages. Adipose tissue is derived from preadipocytes. Its main role is to store energy in the form of lipids, although it also cushions and insulates the body. Far from being hormonally inert, adipose tissue has, in recent years, been recognized as a major endocrine organ, as it produces hormones such as leptin, estrogen, resistin, and cytokines (especially TNFα). In obesity, adipose tissue is also implicated in the chronic release of pro-inflammatory markers known as adipokines, which are responsible for the development of metabolic syndrome, a constellation of diseases, including type 2 diabetes, cardiovascular disease and atherosclerosis. The two types of adipose tissue are white adipose tissue (WAT), which stores energy, and brown adipose tissue (BAT), which generates body heat. The formation of adipose tissue appears to be controlled in part by the adipose gene. Adipose tissue – more specifically brown adipose tissue – was first identified by the Swiss naturalist Conrad Gessner in 1551.

<span class="mw-page-title-main">Adiponectin</span> Mammalian protein found in Homo sapiens

Adiponectin is a protein hormone and adipokine, which is involved in regulating glucose levels and fatty acid breakdown. In humans, it is encoded by the ADIPOQ gene and is produced primarily in adipose tissue, but also in muscle and even in the brain.

<span class="mw-page-title-main">Resistin</span> Mammalian protein found in Homo sapiens

Resistin also known as adipose tissue-specific secretory factor (ADSF) or C/EBP-epsilon-regulated myeloid-specific secreted cysteine-rich protein (XCP1) is a cysteine-rich peptide hormone derived from adipose tissue that in humans is encoded by the RETN gene.

<span class="mw-page-title-main">Ghrelin</span> Peptide hormone involved in appetite regulation

Ghrelin is a hormone primarily produced by enteroendocrine cells of the gastrointestinal tract, especially the stomach, and is often called a "hunger hormone" because it increases the drive to eat. Blood levels of ghrelin are highest before meals when hungry, returning to lower levels after mealtimes. Ghrelin may help prepare for food intake by increasing gastric motility and stimulating the secretion of gastric acid.

<span class="mw-page-title-main">Agouti-related peptide</span> Mammalian protein found in Homo sapiens

Agouti-related protein (AgRP), also called agouti-related peptide, is a neuropeptide produced in the brain by the AgRP/NPY neuron. It is synthesized in neuropeptide Y (NPY)-containing cell bodies located in the ventromedial part of the arcuate nucleus in the hypothalamus. AgRP is co-expressed with NPY and acts to increase appetite and decrease metabolism and energy expenditure. It is one of the most potent and long-lasting of appetite stimulators. In humans, the agouti-related peptide is encoded by the AGRP gene.

<span class="mw-page-title-main">Leptin receptor</span> Type I cytokine receptor

Leptin receptor, also known as LEP-R or OB-R, is a type I cytokine receptor, a protein that in humans is encoded by the LEPR gene. LEP-R functions as a receptor for the fat cell-specific hormone leptin. LEP-R has also been designated as CD295. Its location is the cell membrane, and it has extracellular, trans-membrane and intracellular sections.

<span class="mw-page-title-main">Fibroblast growth factor 21</span>

Fibroblast growth factor 21 is a protein that in mammals is encoded by the FGF21 gene. The protein encoded by this gene is a member of the fibroblast growth factor (FGF) family and specifically a member of the endocrine subfamily which includes FGF23 and FGF15/19. FGF21 is the primary endogenous agonist of the FGF21 receptor, which is composed of the co-receptors FGF receptor 1 and β-Klotho.

Douglas L. Coleman was a scientist and professor emeritus at the Jackson Laboratory, in Bar Harbor, Maine. His work predicted that there exists a hormone that can cause mice to feel full, and that a mutation in the gene encoding this hormone can lead to obesity. The gene and corresponding hormone were discovered about 20 years later by Jeffrey M. Friedman, Rudolph Leibel, and their research teams at Rockefeller University, which Friedman named leptin.

<span class="mw-page-title-main">Teleost leptins</span>

Teleost leptins are a family of peptide hormones found in fish (teleostei) that are orthologs of the mammalian hormone leptin. The teleost and mammalian leptins appear to have similar functions, namely, regulation of energy intake and expenditure.

<span class="mw-page-title-main">Jeffrey Flier</span> American physician

JeffreyFlier is an American physician, endocrinologist; widely cited scientist; the Higginson Professor of Medicine and Physiology at Harvard Medical School; and a Distinguished Service Professor at the same institution. He was the 21st Dean of the Faculty of Medicine at Harvard University from 2007 to 2016.

Mladen Vranic, MD, DSc, O.C., O.Ont, FRSC, FRCP(C), FCAHS, Canadian Medical Hall of Fame[CMHF] April 3, 1930 – June 18, 2019, was a Croatian-born diabetes researcher, best known for his work in tracer methodology, exercise and stress in diabetes, the metabolic effects of hormonal interactions, glucagon physiology, extrapancreatic glucagon, the role of the direct and indirect metabolic effects of insulin and the prevention of hypoglycemia. Vranic was recognized by a number of national and international awards for his research contributions, mentoring and administration including the Orders of Canada (Officer) and Ontario.

Metreleptin, sold under the brand name Myalept among others, is a synthetic analog of the hormone leptin used to treat various forms of dyslipidemia. It has been approved in Japan for metabolic disorders including lipodystrophy and in the United States as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystrophy.

<span class="mw-page-title-main">Christos Socrates Mantzoros</span> Greek American physician and scientist

Christos Socrates Mantzoros is a Greek American physician-scientist, practicing internist-endocrinologist, teacher and researcher. He is a professor of medicine at Harvard Medical School and an adjunct professor at Boston University School of Medicine. He currently serves as the chief of endocrinology, diabetes and metabolism at the VA Boston Healthcare System, where he created de novo a leading academic division true to its tripartite mission and as the founding director of human nutrition at Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School. Finally, he holds the editor-in-chief position of the journal Metabolism: Clinical and Experimental.

<span class="mw-page-title-main">Pathophysiology of obesity</span>

Pathophysiology of obesity is the study of disordered physiological processes that cause, result from, or are otherwise associated with obesity. A number of possible pathophysiological mechanisms have been identified which may contribute in the development and maintenance of obesity.

Rexford Sefah Ahima is a Professor of Medicine, Public Health and Nursing; Bloomberg Distinguished Professor of Diabetes at the Johns Hopkins Medical School; and the Director of the Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins University School of Medicine. Ahima's research focuses on central and peripheral actions of adipocyte hormones in energy homeostasis, and glucose and lipid metabolism.

<span class="mw-page-title-main">Ana Domingos</span> Portuguese neuroscientist

Ana I. Domingos is a Portuguese neuroscientist specialising in the treatment of obesity independently of food intake. Domingos is a full Professor of Neuroscience at the Department of Physiology, Anatomy and Genetics of the University of Oxford in the United Kingdom. Domingos is also a fellow, tutor and the director of studies in medicine at Lady Margaret Hall, Oxford.

<span class="mw-page-title-main">Alexei Kharitonenkov</span> Russian biochemist

Alexei Kharitonenkov is a Russian-American researcher best known for his discoveries of endocrine functions of Fibroblast Growth Factor 21 (FGF21) and its prospects in developing novel therapies for metabolic diseases. He is also known for his landmark identification of the signal-regulatory family of proteins (SIRPs), and their corresponding protein-tyrosine phosphatases, which helped unveil the molecular machinery of immune self-recognition and their potential for the development of drugs to fight cancer.

References

  1. ↑ "Meet the 2020 Laureates: Eleftheria Maratos-Flier, MD". Endocrine News. 2020-03-05. Retrieved 2022-03-19.
  2. 1 2 "SSIB 2017 MARS Speakers". www.ssib.org. Retrieved 2022-03-19.
  3. ↑ Flier, Jeffrey S.; Maratos-Flier, Eleftheria (2007). "What Fuels Fat". Scientific American. 297 (3): 72–81. Bibcode:2007SciAm.297c..72F. doi:10.1038/scientificamerican0907-72. PMID   17784627 . Retrieved 2022-03-18.
  4. ↑ "Can't resist candy? You may have this mutation". PBS NewsHour. 2017-05-08. Retrieved 2022-03-18.
  5. 1 2 Ahima, Rexford S.; Prabakaran, Daniel; Mantzoros, Christos; Qu, Daqing; Lowell, Bradford; Maratos-Flier, Eleftheria; Flier, Jeffrey S. (1996-07-01). "Role of leptin in the neuroendocrine response to fasting". Nature. 382 (6588): 250–252. Bibcode:1996Natur.382..250A. doi:10.1038/382250a0. ISSN   0028-0836. PMID   8717038. S2CID   4331304.
  6. 1 2 Qu, Daqing; Ludwig, David S.; Gammeltoft, Steen; Piper, Megan; Pelleymounter, Mary Ann; Cullen, Mary Jane; Mathes, Wendy Foulds; Przypek, Jeanne; Kanarek, Robin; Maratos-Flier, Eleftheria (1996-03-01). "A role for melanin-concentrating hormone in the central regulation of feeding behaviour". Nature. 380 (6571): 243–247. Bibcode:1996Natur.380..243Q. doi:10.1038/380243a0. ISSN   0028-0836. PMID   8637571. S2CID   42701304.
  7. 1 2 Flier, Jeffrey S.; Maratos-Flier, Eleftheria (2018). Harrison's principles of internal medicine. Chapter 394: Pathobiology of Obesity (20th ed.). New York: McGraw Hill. ISBN   978-1-259-64403-0. OCLC   1029074059.
  8. 1 2 Maratos-Flier, Elephteria (2020). Obesity chapter in Williams textbook of endocrinology. Shlomo Melmed, Richard J. Auchus, Allison B. Goldfine, Ronald Koenig, Clifford J. Rosen, Robert Hardin Preceded by: Williams (14 ed.). Philadelphia, PA: Saunders. pp. 1567–1580, Obesity chapter. ISBN   978-0323555968. OCLC   1131863622.
  9. 1 2 Fisher, Ffolliott Martin; Maratos-Flier, Eleftheria (2016). "Understanding the Physiology of FGF21". Annual Review of Physiology. 78: 223–241. doi: 10.1146/annurev-physiol-021115-105339 . ISSN   1545-1585. PMID   26654352.
  10. ↑ Shaywitz, David. "Power couples: common in medicine, rare in business?". Forbes. Retrieved 2022-03-02.
  11. ↑ Flier, Jeffrey S. (2012-09-01). "Hormone resistance in diabetes and obesity: insulin, leptin, and FGF21". The Yale Journal of Biology and Medicine. 85 (3): 405–414. ISSN   1551-4056. PMC   3447204 . PMID   23012588.
  12. ↑ "ORCID". orcid.org. Retrieved 2022-03-02.
  13. 1 2 "American Chemical Society Award Winners, Washington, D.C." Analytical Chemistry. 43 (12): 63A–73A. 1971-10-01. doi:10.1021/ac60306a706. ISSN   0003-2700.
  14. 1 2 "Alumni Award Recipients". alumni.icahn.mssm.edu. Retrieved 2022-03-19.
  15. 1 2 "Eleftheria Maratos-Flier, MD".
  16. ↑ "New Appointments to Full Professor (12/22/10)". hms.harvard.edu. Retrieved 2022-03-19.
  17. ↑ "Team". Broad Institute. 2008-04-23. Retrieved 2022-03-19.
  18. ↑ "Eleftheria Maratos-Flier". grantome.com.
  19. ↑ "Meet Our Endocrinology, Diabetes and Metabolism Experts". www.bidmc.org. Retrieved 2022-03-19.
  20. ↑ Rader, Daniel J.; Maratos-Flier, Eleftheria; Nguyen, Amanda; Hom, Doug; Ferriere, Michael; Li, Yifang; Kompa, Jill; Martic, Miljen; Hinder, Markus; Basson, Craig T.; Yowe, David (2022-01-01). "LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia". The Journal of Clinical Endocrinology and Metabolism. 107 (1): e57–e70. doi:10.1210/clinem/dgab624. ISSN   1945-7197. PMC   8914500 . PMID   34431493.
  21. 1 2 "Scopus preview - Maratos-Flier, Eleftheria - Author details - Scopus". www.scopus.com. Retrieved 2022-03-19.
  22. ↑ "An Appetite for Research: Q&A with Eleftheria Maratos-Flier, MD". Endocrine News. 2020-10-05. Retrieved 2022-03-02.
  23. ↑ Badman, Michael K.; Pissios, Pavlos; Kennedy, Adam R.; Koukos, George; Flier, Jeffrey S.; Maratos-Flier, Eleftheria (2007-06-01). "Hepatic Fibroblast Growth Factor 21 Is Regulated by PPARα and Is a Key Mediator of Hepatic Lipid Metabolism in Ketotic States". Cell Metabolism. 5 (6): 426–437. doi: 10.1016/j.cmet.2007.05.002 . PMID   17550778.
  24. ↑ Fisher, ffolliott M.; Kleiner, Sandra; Douris, Nicholas; Fox, Elliott C.; Mepani, Rina J.; Verdeguer, Francisco; Wu, Jun; Kharitonenkov, Alexei; Flier, Jeffrey S.; Maratos-Flier, Eleftheria; Spiegelman, Bruce M. (2012-02-01). "FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis". Genes & Development. 26 (3): 271–281. doi:10.1101/gad.177857.111. ISSN   0890-9369. PMC   3278894 . PMID   22302939.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.